T-DXd
Physiologically based pharmacokinetic model to predict drug-drug Interactions with the antibody-drug conjugate trastuzumab deruxtecan
This site is for U.S. Healthcare Professionals only.
Publications
This section includes selected Daiichi Sankyo-sponsored publications.
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
T-DXd
Breast Cancer
First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: Multicenter, open-label, phase 1b/2 BEGONIA platform trial
Schmid P, Im SA, Nowecki Z,et al.
Nat Cancer. 2026. doi: 10.1038/s43018-026-01181-8.
Quizartinib
Hematology
The effect of Eeavirenz and rufinamide on the pharmacokinetics and safety of quizartinib: Two phase 1 studies in healthy participants
Yoo Y, Zahir H, Inaba S, et al.
Clin Transl Sci. 2026;19(6):e70619. doi: 10.1111/cts.70619.
Pipeline Compounds
Other/Multi
Preclinical evaluation and mechanistic analysis of antitumor effects of the novel anti-CD147 antibody DS-1471a in liver cancer models
Yuita H, Watanabe S, Tsukada J, et al.
Invest New Drugs. 2026. doi: 10.1007/s10637-026-01621-3.
T-DXd
Gastric Cancer
Human epidermal growth factor receptor 2 quantification using computational pathology to identify novel biomarkers for trastuzumab deruxtecan-treated human epidermal growth factor receptor 2-positive dastric cancer
Kapil A, Failmezger H, Fu Y, et al.
JCO Precis Oncol. 2026;10(5):e2500823. doi: 10.1200/PO-25-00823.
Other/Multi
Other/Multi
Pathophysiological and molecular features of DXd ADC-related interstitial pneumonitis in cynomolgus monkeys
Kumagai K, Iguchi T, Kubota K, Sakurai K, Tsuchiya Y, Chiba K.
Cancer Sci. 2026. doi: 10.1111/cas.70424.
Edoxaban
Cardiovascular - AF
Edoxaban for stroke prevention in atrial fibrillation in Spain and Portugal: 4-year follow-up of the observational ETNA-AF-Europe study
Barón-Esquivias G, Monteiro P, Santiago-Ruiz JL, et al.
J Clin Med. 2026;15(11):4085. doi: 10.3390/jcm15114085.
T-DXd
Breast Cancer
Estimating the societal impact of medical interventions: a case study in metastatic breast cancer
Tsotra F, Dunton K, Rosenlund M, Steinbeck L, Johal S.
J Comp Eff Res. 2026;15(6):e260005. doi: 10.57264/cer-2026-0005.
Dato-DXd
Breast Cancer
Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study
Schmid P, Wang HC, Lynce F, et al.
Ann Oncol. 2026:S0923-7534(26)00877-X. doi: 10.1016/j.annonc.2026.05.693.
Dato-DXd
Lung Cancer
TROPION-Lung14 study protocol: A phase III study of osimertinib in combination with datopotamab deruxtecan versus osimertinib alone as first-line treatment for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer
Lu S, Pulla MP, Mascarenhas E, et al.
Ther Adv Med Oncol. 2026;18:17588359261430561. doi: 10.1177/17588359261430561.
DataSource by Daiichi Sankyo website provides U.S.
healthcare professionals with high quality, fair balanced, evidence-based medical information.
The information provided is for education purposes only and is not intended as medical advice.
Please choose an option below